- Home
- ADPT vs EDN Comparison
ADPT vs EDN Comparison
Compare ADPT & EDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- EDN
- Stock Information
- Founded
- ADPT 2009
- EDN 1992
- Country
- ADPT United States
- EDN Argentina
- Employees
- ADPT N/A
- EDN N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- EDN Electric Utilities: Central
- Sector
- ADPT Health Care
- EDN Utilities
- Exchange
- ADPT Nasdaq
- EDN Nasdaq
- Market Cap
- ADPT 1.4B
- EDN 1.5B
- IPO Year
- ADPT 2019
- EDN 2007
- Fundamental
- Price
- ADPT $9.53
- EDN $32.66
- Analyst Decision
- ADPT Buy
- EDN
- Analyst Count
- ADPT 6
- EDN 0
- Target Price
- ADPT $9.83
- EDN N/A
- AVG Volume (30 Days)
- ADPT 2.5M
- EDN 122.9K
- Earning Date
- ADPT 05-01-2025
- EDN 03-11-2025
- Dividend Yield
- ADPT N/A
- EDN N/A
- EPS Growth
- ADPT N/A
- EDN N/A
- EPS
- ADPT N/A
- EDN 0.21
- Revenue
- ADPT $189,527,000.00
- EDN $2,097,707,542.00
- Revenue This Year
- ADPT $25.00
- EDN $51.74
- Revenue Next Year
- ADPT $20.38
- EDN N/A
- P/E Ratio
- ADPT N/A
- EDN $7.99
- Revenue Growth
- ADPT 8.61
- EDN 37.57
- 52 Week Low
- ADPT $2.99
- EDN $13.78
- 52 Week High
- ADPT $10.28
- EDN $51.69
- Technical
- Relative Strength Index (RSI)
- ADPT 59.79
- EDN 47.50
- Support Level
- ADPT $8.50
- EDN $32.51
- Resistance Level
- ADPT $9.69
- EDN $37.08
- Average True Range (ATR)
- ADPT 0.41
- EDN 2.50
- MACD
- ADPT -0.01
- EDN -0.30
- Stochastic Oscillator
- ADPT 77.52
- EDN 12.70
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.